I Gede Eka Wiratnaya, MD, PhD, SpOT(K)

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies

Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers